Jialei Wang
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI (NCT06652048) | Jialei Wang | 2024-10-01 |
Track Jialei Wang automatically
Every clearance here is in the API, with alerts when new ones post.